

## Bone Marrow Examination

[View the current Bone Marrow Examination InDepth page on BioPortfolio.com \(PDF\)](#)

([http://www.bioportfolio.com/indepth/Bone\\_Marrow\\_Examination.html](http://www.bioportfolio.com/indepth/Bone_Marrow_Examination.html)) - Regularly Updated.



### Recent Publications on Bone Marrow Examination:

- [Severe gastrointestinal bleeding and thrombocytopenia in a child with an anti-GATA1 autoantibody.](#)  
*We describe a patient, who developed during the first week of life...*20th November, 2009  
Department of Pediatrics [L.W., K.F., S.L., C.Y., C.W., C.F.], Department- Pediatr Res. 2009 Nov 17. ([DOI Direct Link](#))
- [Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia.](#)  
*Essential thrombocythemia is a hematological disorder characterized by...*20th November, 2009  
Centro Emofilia e Trombosi, Unita Operativa Medicina Interna 2,- Blood Coagul Fibrinolysis. 2009 Nov 17. ([DOI Direct Link](#))
- [Indications and Diagnostic Utility of Bone Marrow Examination in Different Bone Marrow Disorders in Iran.](#)  
*The shortage of published literature regarding the indications for bone...*20th November, 2009  
Department of Pathology, Rasoul Akram Hospital, School of Medicine, Iran- Lab Hematol. 2009 Dec 1;15(4):38-44. ([DOI Direct Link](#))
- [Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.](#)  
*A 56-year-old woman with acute myelomonocytic leukemia underwent...*12th November, 2009  
Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato,- Int J Hematol. 2009 Nov 11. ([DOI Direct Link](#))
- [Invasion of erythroblasts by Plasmodium vivax: A new mechanism contributing to malarial anemia.](#)  
*Severe malarial anemia causes considerable mortality and morbidity in...*10th November, 2009  
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of- Ultrastruct Pathol. 2009 Oct;33(5):236-42.
- [Keratotic vascular papules over the feet: a case of Waldenstrom's macroglobulinaemia-associated cutaneous macroglobulinosis.](#)  
*Summary Waldenstrom's macroglobulinaemia (WM) is a plasma-cell dyscrasia...*31st October, 2009  
Department of Dermatology, King Edward Memorial Hospital and Seth GS- Clin Exp Dermatol. 2009 Oct 23. ([DOI Direct Link](#))
- [\[50-year-old woman with elevated haemoglobin and iron deficiency\]](#)  
*BACKGROUND: Elevated haemoglobin and erythrocytosis are frequent causes...*29th October, 2009  
Medisinsk avdeling, Universitetssykehuset Nord-Norge - Harstad, 9480- Tidsskr Nor Laegeforen. 2009 Sep 24;129(18):1878-81. ([DOI Direct Link](#))
- [\[Routine blood test and bone marrow examination in visceral leishmaniasis patients in Kashi Prefecture\]](#)

*The examinations of blood and bone marrow in 125 patients with visceral...*27th October, 2009  
Department of Laboratory Medicine, Third Hospital of Kashi Prefecture in- Zhongguo Ji Sheng Chong  
Xue Yu Ji Sheng Chong Bing Za Zhi. 2009

- [\[An atypical case of cardiac amyloidosis\]](#)

*The described report deals with the case of a patient with diagnosis of...*22nd October, 2009  
UOC Medicina Cardiovascolare e RM Lab, Fondazione G. Monasterio- Recenti Prog Med. 2009  
May;100(5):247-52.

- [Videos in clinical medicine. Bone marrow aspiration and biopsy.](#)

*INTRODUCTION: Visceral leishmaniasis is a potentially life-threatening...*17th October, 2009  
Division of Hematology and Oncology, Department of Pediatrics, Doernbecher- N Engl J Med. 2009  
Oct 8;361(15):e28. ([DOI Direct Link](#))

- [Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report.](#)

*INTRODUCTION: Visceral leishmaniasis is a potentially life-threatening...*16th October, 2009  
- J Med Case Reports. 2009 Jun 25;3:7265. ([DOI Direct Link](#))

- [Classification of anemia for gastroenterologists.](#)

*Most anemia is related to the digestive system by dietary deficiency,...*10th October, 2009  
Department of Hematology, University Hospital Lozano Blesa, University of- World J Gastroenterol.  
2009 Oct 7;15(37):4627-37.

- [\[Evaluation of trainee doctors' skills\]](#)

*The objective was to perform a needs assessment of trainee doctors'...*26th September, 2009  
Borneonkologisk Laboratorium 5704, De Paediatriske Klinikker, Juliane- Ugeskr Laeger. 2009 Sep  
14;171(38):2742-5.

- [Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.](#)

*Bone marrow examination has become increasingly important for the...*24th September, 2009  
Medical College of Virginia Hospitals of Virginia Commonwealth University,- J Clin Lab Anal.  
2009;23(5):259-307. ([DOI Direct Link](#))

- [Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?](#)

*Acquired pure red cell aplasia (PRCA) can be primary or secondary to other...*18th September, 2009  
Section of Hematology/Oncology, Department of Medicine, Medical College of- Int J Hematol. 2009  
Sep 18. ([DOI Direct Link](#))

## BioNews Results for Bone Marrow Examination

- [Pigmented villonodular synovitis in a patient with prior history of breast cancer](#)  
*Hemonctoday: Oct 12 2009 3:01PM Matching: bone marrow examination*

## Bone Marrow Examination Patents:



- 5874412- [Bis-anthracyclines with high activity against doxorubicin resistant tumors](#)

- 6437105- [Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents](#)
- 6566140- [Inhibition of coagulation in blood and blood products](#)
- 6582725- [Human PEA3 is a tumor suppressor for cancer cells](#)
- 6593342- [Pharmaceutical compositions comprising 2-quinolones](#)
- 6645983- [Pharmaceutical compositions comprising 4-quinolones for treating cancers](#)
- 6673907- [Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics](#)
- 6680300- [Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents](#)
- 6682734- [Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma](#)
- 6682940- [Products and methods for single parameter and multiparameter phenotyping of cells](#)
- 6683059- [Mini-E1A gene and gene products](#)
- 6403381- [Inhibition of coagulation in blood and blood products](#)
- 6399061- [Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma](#)
- 6395712- [Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy](#)
- 5922688- [PEA3 is a tumor suppressor](#)
- 6010696- [Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells](#)
- 6107020- [Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof](#)
- 6172212- [Pea3 is a tumor suppressor](#)
- 6183756- [Methods for prevention and/or treatment of thrombocytopenia](#)
- 6197754- [Suppression of tumor growth by a mini-E1A gene](#)
- 6248351- [Human PEA3 is a tumor suppressor for cancer cells](#)
- 6326356- [Suppression of neu overexpression using a mini-E1A gene](#)
- 6331284- [P202 is a tumor suppressor](#)
- 6355784- [Methods and compositions for the manufacture of halogenated anthracyclines with increased antitumor activity, other anthracyclines, halogenated sugars, and glycosyl donors](#)
- 6723351- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)
- 6733792- [Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies](#)
- 7309316- [Magnetic needle biopsy](#)
- 7323168- [Immunotherapy for chronic myelocytic leukemia](#)
- 7351589- [Products and methods for single parameter and multiparameter phenotyping of cells](#)
- 7364906- [Products and methods for single parameter and multiparameter phenotyping of cells](#)
- 7381560- [Expression and use of anti-CD20 antibodies](#)
- 7393862- [Method using 3-\(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione for treatment of certain leukemias](#)
- 7422739- [Anti-CD20 antibodies](#)
- 7435726- [Compositions and methods for the treatment of cancer](#)
- 7521071- [Formulation of oral compositions comprising arsenic trioxide and methods of use thereof](#)
- 7537907- [Products and methods for single parameter and multiparameter phenotyping of cells](#)
- 7138147- [Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies](#)
- 7109177- [Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics](#)
- 7070954- [Isolated SH3 genes associates with myeloproliferative disorders and leukemia and uses thereof](#)
- 6759045- [Immunotherapy for chronic myelocytic leukemia](#)
- 6770304- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)
- 6828157- [Products and methods for single parameter and multiparameter phenotyping of cells](#)
- 6855339- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)

- 6861076- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)
- 6875183- [Biopsy needle](#)
- 6884439- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)
- 6982096- [Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol](#)
- 7005424- [Nucleic acid encoding an E1A gene product sensitizes HER-2/neu overexpressing cancer cells to chemotherapy](#)
- 7033618- [Methods of administering gaultherin-containing compositions](#)
- 7557090- [Anthracycline antibiotics and methods of treating cancer using the same](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

